Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701725 | 1.00 | KMT2A (0.53) | KMT2AMEN1LMNAALDH1A1KDM4E | |
| SCHEMBL4697709 | 0.85 | MAPT (0.51) | KMT2AMEN1LMNAALDH1A1KDM4E | |
| SCHEMBL4697713 | 0.85 | MAPT (0.51) | KMT2AMEN1LMNAALDH1A1KDM4E | |
| SCHEMBL4699456 | 0.83 | LMNA (0.44) | KMT2AMEN1LMNAALDH1A1KDM4E | |
| SCHEMBL4699454 | 0.83 | LMNA (0.44) | KMT2AMEN1LMNAALDH1A1KDM4E | |
| SCHEMBL398854 | 0.81 | MAPT (0.48) | KMT2AMEN1LMNAKDM4EGAA | |
| SCHEMBL398853 | 0.81 | MAPT (0.48) | KMT2AMEN1LMNAKDM4EGAA | |
| SCHEMBL4697823 | 0.81 | MAPT (0.48) | KMT2AMEN1LMNAALDH1A1KDM4E | |
| SCHEMBL4697819 | 0.81 | MAPT (0.48) | KMT2AMEN1LMNAALDH1A1KDM4E | |
| SCHEMBL4698013 | 0.78 | MAPT (0.46) | KMT2AMEN1LMNAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309544-B1 | COMPOUNDS ACTING AS MELANOCORTIN RECEPTOR LIGANDS | ACURE PHARMA AB (SE) | 2008-11-05 | — | — | EP | claimed |
| US-7153881-B2 | Compounds acting as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2006-12-26 | — | — | US | claimed |
| EP-1309544-B1 | COMPOUNDS ACTING AS MELANOCORTIN RECEPTOR LIGANDS | ACURE PHARMA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-7153881-B2 | Compounds acting as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2006-12-26 | — | — | US | disclosed |
| US-20040019094-A1 | Compounds acting as melanocortin receptor ligands | HPF IP HOLDING S.A. (LU) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019094-A1 | Compounds acting as melanocortin receptor ligands | MC1R, MC3R, MC5R | KMT2A 2662/4885MEN1 383/4885LMNA 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.